Some individuals with rheumatoid arthritis (RA) are treated with a monthly infusion of the biologic tocilizumab (Actemra—Genentech). However, the drug is now in short supply because of the surge in COVID-19 cases.

Thousands of patients have reported experiencing a wide range of physical and mental health consequences that persist after a COVID-19 infection. Patients with post-COVID-19 conditions, sometimes referred to as “COVID long-haulers,” often experience issues four or more weeks after being infected with the virus. Many of these patients routinely seek medical treatment for relief of their symptoms.